QAL 964Alternative Names: QAL-964
Latest Information Update: 26 Jun 2015
At a glance
- Originator Novartis
- Class Antirheumatics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 16 May 2015 Novartis terminates phase II trial in Rheumatoid arthritis in Hungary and Greece (PO) (EudraCT2013-003493-27)
- 08 Apr 2014 Phase-II clinical trials in Rheumatoid arthritis in Hungary (PO)